Ambiq Micro, Inc. filings document the public-company record for a fabless semiconductor issuer focused on ultra-low-power edge AI chips and software. Its SEC disclosures include S-1 registration materials for common stock offerings, 8-K reports on quarterly and annual financial results, and exchange-listing details for AMBQ common stock on the New York Stock Exchange.
Proxy and current-report filings cover shareholder voting matters, director elections, audit-firm ratification, board composition, executive compensation, equity awards, and other governance subjects. Capital-structure disclosures identify common stock terms and offering-related updates.
Ambiq Micro, Inc. Chief Executive Officer and director Esaka Fumihide reported exercising stock options and acquiring additional common shares. On October 7, 2025, a stock option for 53,660 shares with a $5.88 exercise price was exercised, converting into 53,660 shares of common stock at $5.88 per share.
Following this transaction, Esaka Fumihide directly owned 230,573 shares of Ambiq Micro common stock, and the reported option position was reduced to zero. The option had vested over time, with vesting beginning in 2016 and subject to continued service and the issuer’s repurchase rights.
Ambiq Micro, Inc. director Joseph A. Tautges reported a sale of company stock. On January 26, 2026, he sold 7,800 shares of Ambiq Micro common stock at $31 per share in a single open-market transaction. After this sale, he beneficially owns 48,746 common shares, held in direct ownership form.
Ambiq Micro, Inc. director and Chief Technology Officer Hanson Scott McLean reported selling 10,000 shares of common stock on 01/26/2026 at $31 per share. After this transaction, he beneficially owns 122,818 shares of Ambiq Micro common stock, held directly.
Ambiq Micro, Inc. is registering 2,679,600 shares of common stock at a public offering price of $31.00 per share, including 2,636,651 shares sold by the company and 42,949 shares sold by existing stockholders, with an underwriter option for up to 401,940 additional shares. Ambiq expects gross proceeds of $83,067,600, yielding $76,832,010 in proceeds to the company and $1,251,534 to selling stockholders before expenses.
The company designs ultra‑low power semiconductor SoCs based on its SPOT® platform to run AI workloads at the edge with two to five times lower power consumption than conventional designs, and its products power over 290 million devices. Net sales were $76.1 million in 2024 and $65.5 million in 2023, with a net loss of $39.7 million in 2024 and $50.3 million in 2023. For 2025, Ambiq preliminarily estimates net sales of $71.77–$72.47 million, with gross margin improving from 31.9% in 2024 to an estimated 43.7% in 2025 and non‑GAAP gross margin to 44.3–44.6%.
Ambiq is shifting away from Mainland China, where 2024 net sales of $38.0 million are expected to fall sharply in 2025, while net sales outside Mainland China are estimated to rise to about $65.3–$66.4 million and represent roughly 91–91.6% of total net sales.
Ambiq Micro, Inc. released preliminary, estimated unaudited financial results for the year ended December 31, 2025. The company expects net sales between $71,770 thousand and $72,470 thousand, with net sales outside Mainland China between $65,331 thousand and $66,368 thousand.
Net sales in Mainland China are estimated between $6,102 thousand and $6,439 thousand, representing about 8.4% to 9.0% of total net sales, while sales outside Mainland China represent about 91.0% to 91.6%. Estimated gross profit ranges from $31,359 thousand to $31,667 thousand, with a gross margin of 43.7%.
On a non-GAAP basis, Ambiq estimates gross profit between $31,792 thousand and $32,300 thousand and non-GAAP gross margin between 44.3% and 44.6%. These figures are preliminary, based on internal records, have not been audited or reviewed by KPMG LLP, and may change after completion of the year-end closing and audit.
Ambiq Micro, Inc. is conducting a 2,200,000‑share common stock offering, including 2,157,051 new shares from the company and 42,949 shares from selling stockholders. Ambiq will receive the proceeds from its primary shares, while existing holders will receive any proceeds from their sales. The underwriters also have an option to buy up to 330,000 additional shares. There were 18,238,462 shares outstanding as of September 30, 2025.
Ambiq designs ultra‑low power semiconductor systems‑on‑chip and software for edge AI applications, built on its proprietary SPOT platform. Net sales were $76.1 million in 2024 and are estimated at $71.8–$72.5 million for 2025, but gross profit is projected to rise to about $31.4–$31.7 million, lifting gross margin from 31.9% to 43.7%. The company remains loss‑making, with a 2024 net loss of $39.7 million and a nine‑month 2025 net loss of $25.8 million.
Ambiq is rapidly shifting away from Mainland China: 2024 net sales were split evenly between Mainland China and other regions, while 2025 net sales outside Mainland China are estimated at $65.3–$66.4 million, or over 91% of total net sales, with Mainland China sales falling more than 83%. Ambiq qualifies as an emerging growth and smaller reporting company, allowing reduced disclosure and delayed adoption of some new accounting standards.
Ambiq Micro, Inc. director files initial ownership report with no holdings
Ambiq Micro, Inc. director Bernard Bennett Banks filed an initial beneficial ownership report as a reporting person of the company. The filing identifies him as a director and confirms that, at the time of the reported event on 01/05/2026, he did not beneficially own any Ambiq Micro securities. The remarks section explicitly states that no securities are beneficially owned, and both the non-derivative and derivative ownership tables contain no reported positions.
Ambiq Micro, Inc. expanded its Board of Directors from six to seven members and appointed Dr. Bernard B. Banks to fill the new seat, effective January 5, 2026. He will serve as a Class III director until the company’s 2028 annual meeting of stockholders, when he is expected to stand for election.
Dr. Banks is Director of Rice University’s Doerr Institute for New Leaders and previously served on the senior leadership team and faculty at Northwestern University’s Kellogg School of Management for six years. He is a retired U.S. Army Brigadier General with experience leading organizations from 10 to over 3,000 people and holds a Ph.D. in social-organizational psychology from Columbia University along with multiple graduate degrees from leading institutions.
He will receive compensation under Ambiq Micro’s Non-Employee Director Compensation Policy and has entered into the company’s standard director indemnification agreement.
Ambiq Micro, Inc. reported that its General Counsel, Michele Kim Connors, received equity awards in the form of restricted stock units tied to the company’s common stock. On January 5, 2026, she was granted 23,759 units and a separate grant of 5,483 units, both reported as acquisitions at a price of $0 per share. After these grants, she beneficially owned 29,242 shares of common stock.
The first grant vests over time, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal quarterly installments, assuming continued service under the company’s 2025 Equity Incentive Plan. The second grant vests with 25% of the shares on April 1, 2026, and the remaining shares vesting in equal quarterly installments on the same service condition.